Kurzfassung

Autoimmune type A gastritis (AG) is a chronic inflammatory gastric disease limited to the fundus and body of the stomach. AG is silent and only becomes symptomatic years later when the inflammatory gastric lesion progresses to chronic atrophic gastritis that manifests as either vitamin B12-deficient pernicious anemia or antecedent iron deficiency anemia. The prevalence of AG and atrophic gastritis ranges from 7.8% to 19.5% and from 3.5% to 10.7%, respectively. Autoimmune induced destruction...Autoimmune type A gastritis (AG) is a chronic inflammatory gastric disease limited to the fundus and body of the stomach. AG is silent and only becomes symptomatic years later when the inflammatory gastric lesion progresses to chronic atrophic gastritis that manifests as either vitamin B12-deficient pernicious anemia or antecedent iron deficiency anemia. The prevalence of AG and atrophic gastritis ranges from 7.8% to 19.5% and from 3.5% to 10.7%, respectively. Autoimmune induced destruction of the gastric mucosa via anti gastric parietal cells autoantibodies and, in a later stage anti intrinsic factor autoantibodies directed against the gastric chief cells, is subsequently replaced by new gastric cells which are able to produce and secrete Chromogranin A. This relevant morphological change is defined as neuroendocrine metaplasia and is regarded as a precancerous clinical stage.
Prevalence of AG and pernicious anemia is increased 5-fold in patients with type 1 diabetes and/or autoimmune thyroid diseases. These observations suggest that patients with endocrine autoimmune diseases should be regularly screened as close follow-up of patients with gastric autoantibodies and increased chromogranin A could lead to early identification of patients with gastric neuroendocrine dysplasia and associated iron and/or vitamin B12-deficient anemia requiring timely and warranted therapy.» weiterlesen» einklappen